

## **SUCHETA TELANG, M.B.B.S.**

505 South Hancock Street, #423

Louisville, Kentucky 40202

(502) 852-3679 (phone)

(502) 852-3661 (fax)

[sucheta.telang@louisville.edu](mailto:sucheta.telang@louisville.edu)

---

### **EDUCATION**

- 1993 **M.B.B.S.**, Delhi University, New Delhi, India
- 1994-1995 **Pediatric Internship**, University of Connecticut and Connecticut Children's Medical Center, Hartford, CT
- 1995-1997 **Pediatric Residency**, University of Connecticut and Connecticut Children's Medical Center, Hartford, CT
- 1997-2000 **Neonatal/Perinatal Fellowship**, Neonatal/Perinatal Medicine, Baylor College of Medicine and Texas Children's Hospital, Houston, TX

### **ACADEMIC APPOINTMENTS**

- 2001-2002 **Senior Research Associate**, Council for Scientific and Industrial Research & Kalawati Saran Children's Hospital, New Delhi, India
- 2003-*present* **Attending Physician**, Division of Neonatology, Department of Pediatrics University of Louisville Hospital and Kosair Children's Hospital, Louisville KY
- 2003-2014 **Assistant Professor**, Department of Medicine, Division of Medical Oncology, University of Louisville, Louisville, KY
- 2003-2014 **Assistant Professor**, Department of Pediatrics, Division of Neonatology, University of Louisville, Louisville, KY (Joint Appointment)
- 2010-2014 **Assistant Professor**, Department of Biochemistry and Molecular Biology, University of Louisville, KY (Associate Appointment)
- 2014-*present* **Associate Professor**, Department of Medicine, Division of Medical Oncology, University of Louisville, Louisville, KY
- 2014-*present* **Associate Professor**, Department of Pediatrics, Division of Neonatology, University of Louisville, Louisville, KY (Joint Appointment)
- 2014-*present* **Associate Professor**, Department of Biochemistry and Molecular Biology, University of Louisville, KY (Associate Appointment)

### **OTHER POSITIONS**

None

## CERTIFICATION AND LICENSURE

1997            Diplomate, American Board of Pediatrics  
2001, 2008     Certified, American Board of Pediatrics (Neonatology)  
2003            Kentucky State Medical Licensure (#37099, active)  
2003            Indiana State Medical Licensure (#01057610A, active)

## PROFESSIONAL MEMBERSHIPS AND ACTIVITIES

1994-*present* **Fellow**, American Academy of Pediatrics  
2003-*present* **Member**, Molecular Targets Group, Brown Cancer Center  
2013-*present* **Member**, Society for Pediatric Research  
2014-*present* **Member**, American Society for Biochemistry and Molecular Biology

## HONORS AND AWARDS

2003            **Roger Herzig Junior Faculty Research Award**, James Graham Brown Cancer Center, Louisville, Kentucky  
2004            **Roger Herzig Junior Faculty Research Award**, James Graham Brown Cancer Center, Louisville, Kentucky  
2005            **Young Faculty Award**, American Federation for Medical Research  
2005            **Roger Herzig Junior Faculty Research Award**, James Graham Brown Cancer Center, Louisville, Kentucky  
2008            **Roger Herzig Junior Faculty Research Award**, James Graham Brown Cancer Center, Louisville, Kentucky  
2011            **Scientist of the Year**, Julep Ball, Brown Cancer Center, U. of Louisville  
2013            Elected to membership, Society for Pediatric Research

## COMMITTEE ASSIGNMENTS AND ADMINISTRATIVE SERVICES

### University

2006-2008     **Coordinator**, Molecular Targets Seminar Series, Brown Cancer Center  
2006-*present* **Member**, Institutional Animal Care and Use Committee, U. of Louisville  
2008-*present* **Member**, Neonatal Core Curriculum Committee  
2009-*present* **Coordinator**, Extramural Speaker Seminar Series, James Graham Brown Cancer Center  
2011            **Reviewer**, University of Louisville CEGIB Pilot Grant Review Committee  
2012-*present* **Member**, Clinical Study Review Committee, James Graham Brown Cancer Center

### **Non-University**

2009            **Reviewer**, DOD Congressionally Directed Prostate Cancer Research Program  
2014            **Reviewer**, Foundation against Cancer Research Program

### **EDUCATIONAL ACTIVITIES**

#### **Course Teaching:**

**Lecturer**, Biology of Cancer Graduate School course (Bioc675) (“Models of Cancer”)

**Lecturer**, Neonatal Fellowship Program Research and Clinical Core Curriculum (Statistics, Grantsmanship, Respiratory Physiology)

**Lecturer**, Pediatrics Residency Program Neonatology Didactics (“Respiratory Distress Syndrome”, “Respiratory Diseases of the Neonate”, “Chronic Lung Disease”)

**Lecturer**, Radiation Oncology Fellowship Program Core Curriculum (“Radiation Teratology”)

**Faculty Mentor**, Neonatology Fellowship Journal Club

**Instructor**, U of L Medical Embryology Curriculum

#### **Medical Student Clinical Preceptorships:**

Amanda Farris M.D. (2011-2013) University of Louisville

Jonathan Feist M.D. (2011) University of Louisville

#### **Clinical Teaching:**

Resident and fellow teaching on rounds at Kosair Children’s Hospital (Department of Pediatrics residents and Neonatal Medicine clinical fellows)

#### **Research/Laboratory Teaching:**

##### **High School:**

Vanessa Omeokachie (2007) Manual High School

Lindsey Wattlely (2012-2013) North Oldham High School

##### **Undergraduates:**

Harini Chenna (2008) University of Louisville

Lindsey Wattlely (2014) Massachusetts Institute of Technology

##### **Masters Students:**

Natalie Wallis, B.A. (2003-2004) University of Louisville

Jennifer Clark, B.A. (2012-*present*) University of Louisville

**Graduate Students:**

Joshua Thornburg M.S. (2003-2007) University of Louisville

Abdullah Yalcin, D.V.M. (2003-2009) University of Louisville

Jessica Mezzanote (2010) University of Louisville

Whitney Goldsberry (2010-2011) University of Louisville

Alden Klarer (2010-2013) University of Louisville

**Medical Students:**

Mary Ann Rasku (2007-2009) University of Louisville

**Radiation Oncology Residents:**

Jessica Guarnaschelli, M.D. (2005-2006), University of Louisville

**Internal Medicine Residents:**

Neil Crittenden, M.D. (2010), University of Louisville

**Research Post-Doctoral Fellows:**

Kristin Nelson, Ph.D. (2004-2009) University of Louisville

Brian Clem, Ph.D. (2005-2009) University of Louisville

Umesh Goswami, M.B.B.S. (2007-2008) University of Louisville

Deanna Siow, Ph.D. (2009-2011) University of Louisville

Vikas Singh, M.B.B.S. (2011) University of Louisville

Qiaohong Liu, M.D. (2010-2012) University of Louisville

Nadiia Lypova, Ph.D. (2014-*present*), University of Louisville

**Neonatology Fellows:**

Nassir Raoof, D.O. (2013-*present*), University of Louisville

**Hematology/Oncology Fellows:**

Steven Makoni, M.D. (2003-2006), University of Louisville

**Thesis Committees:**

**Department of Pharmacology/Toxicology, University of Louisville**

Ph.D.                      Joshua Thornburg (2008)

**Department of Biochemistry and Molecular Biology, University of Louisville  
(Mentor)**

M.D./Ph.D. Alden Klarer (2010-2013)  
M.S. Jennifer Clark (2012-present)

**CLINICAL ACTIVITIES**

**2003-present Neonatal Intensive Care Inpatient Attending Service**

*Service:* One month per year (average: 30 inpatients/day; for current academic year April and June 2014)

*Sites:* Kosair Children's Hospital Neonatal Intensive Care Unit, Level II and Newborn Nurseries at Norton Hospital and U of L Hospital.

**2003-present Neonatal Intensive Care Attending Physician In-House Overnight and Weekend Coverage:**

*Service:* 36 calls per year (average 80 inpatients)

*Sites:* Kosair Children's Hospital Neonatal Intensive Care Unit, Level II and Newborn Nurseries at Norton Hospital and U of L Hospital.

**2009-2013 Clinical Trial Co-Investigator**

*Service:* Co-Investigator on a Phase I/II trial of Talactoferrin oral solution for nosocomial infection in preterm infants.

*Sites:* Kosair Children's Hospital Neonatal Intensive Care Unit and U of L Hospital.

**2014-2018 Clinical Trial Co-Investigator**

*Service:* Co-Investigator Phase IB/IIA randomized placebo controlled study of the safety and efficacy of once daily dosing of a live biotherapeutic (STP206) in premature very low birth weight and extremely low birth weight neonates.

*Sites:* Kosair Children's Hospital Neonatal Intensive Care Unit and U of L Hospital.

**GRANTS AND CONTRACTS**

## A. Grants

### Past Funding:

1. J.G. Brown Cancer Center P20 Pilot Grant Program

Title: **Role of PFKFB4 in metabolic flux in cancer**

Role: *Principal Investigator*

Period of Support: 03/01/07-02/29/08

Total Award: \$44,750

Total Direct Costs \$44,750

*This grant funds the examination of the function of PFKFB4 in glycolytic flux in neoplastic tissue.*

2. Commonwealth of Kentucky Lung Cancer Research Program Grant

Title: **Targeting 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase- 4 (PFKFB4) in Lung Cancer**

Role: *Principal Investigator (20% effort)*

Period of Support: 09/01/07-08/31/09

Total Award: \$146,623

Total Direct Costs: \$133,293

*This grant funds an analysis of the function of PFKFB4 catalyzed fructose 2,6 bisphosphate in lung tumors.*

3. University of Louisville Advanced Translational Award

Title: **Pre-Clinical Testing of 3-(3-Pyridinyl)-1-(4-Pyridinyl)-2-Propen-1-One In Autoimmunity**

Role: *Co-Investigator*

Period of Support: 06/01/10-05/31/11

Total Award: \$96,192

Total Direct Costs: \$94,306

4. Advanced Cancer Therapeutics (Unrestricted Sponsored Research)

Title: **Pre-clinical Analyses of 3PO and CK37 Derivatives**

Role: *Co-Investigator*

Period of Support: 07/01/10-06/30/12

Total Award: \$ 223,237

Total Direct Costs: \$ 149,823

5. NICHD/NIH (1R44HD057744-01A1)

Title: **Phase I/II Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants**

Role: *Co-Investigator (5% effort)*  
Period of Support: 05/01/09- 8/31/2013  
Total Award: \$165,972  
Total Direct Costs: \$165,972

*The goals of this study are to first ascertain the safety of a recombinant human lactoferrin (Talactoferrin, TLF) when administered orally to premature infants (750-1500 gm) and then determine the efficacy of TLF in reducing the incidence of nosocomial infections in this population of premature infants.*

### **Current Funding:**

#### **1. Commonwealth of Kentucky Lung Cancer Research Program Grant**

Title: **Co-Targeting 6-Phosphofructo-2-Kinase/Fructose-2,6-bisphosphatase - 3 (PFKFB3) and -4 (PFKFB4) as a Strategy Against Lung Cancer**

Role: *Principal Investigator (10% effort)*  
Period of Support: 06/01/14 - 05/31/16  
Total Award: \$150,000  
Total Direct Costs: \$136,364  
2014-2015 Direct Costs: \$68,976

*The goals of this grant are to examine the effects of co-targeting PFKFB3 and PFKFB4 in lung cancer.*

#### **2. NCI/ NIH (1R01CA140991)**

Title: **Targeting Glucose Metabolism in Cancer**

Role: *Principal Investigator (16% effort)*  
Period of Support: 08/01/09-07/31/15 (on no-cost extension)  
Total Award: \$1,289,820  
Total Direct Costs: \$871,500  
2014-2015 Direct Costs: \$153,976

*The goals of this study are to determine the role of PFKFB4 in glycolytic and mitochondrial metabolism in cancer.*

#### **3. American Cancer Society (RSG-10-021-01-CNE)**

Title: **Targeting 6- Phosphofructo-2-Kinase Isoform 4 in Lung Cancer**

Role: *Principal Investigator (25% effort)*  
Period of Support: 01/01/10-12/31/14 (on no-cost extension)  
Total Award: \$719,549

Total Direct Costs: \$599,624  
2013-2014 Direct Costs: \$149,932

*The goals of this study are to determine the function of PFKFB4 in metabolism of lung cancer in vitro and in human lung tumors.*

4. NCR/NIH (1P30GM106396-01) Pilot Grant Program

Title: **Development of Testes PFKFB4 Inhibitors for the Treatment of Lung Cancer**

Role: *Principal Investigator (5% effort)*  
Period of Support: 10/01/13-06/30/15  
Total Award: \$150,000  
Total Direct Costs: \$150,000  
2014-2015 Direct Costs: \$75,000

*The goals of this grant are to develop small molecule inhibitors for lung cancer.*

5. NCR/NIH (1P30GM106396-01)

Title: **Molecular Targets Phase III COBRE**

Role: *Co-investigator/Co-Director, Animal Models Core (10% effort)*  
Period of Support: 07/01/13-06/30/18  
Total Award: \$5,374,446  
Total Direct Costs: \$3,593,630  
2014-2015 Direct Costs: \$750,000 (total), \$156,984 (for Core)

*The goals of this core are to maintain and provide transgenic models of tumorigenesis.*

**B. Contracts**

None

**PATENTS**

**Awarded United States Patents:**

United States Patent #**8,088,385**, **January, 2012**

**PFKFB3 Inhibitors for the Treatment of Proliferative Cancer**

Inventors: Jason Chesney, John O. Trent, **Sucheta Telang**, Brian Clem and Jason Meier



United States Patent #**8,283,332 B2**, **October, 2012**

PFKFB4 Inhibitors and Methods of Using the Same

Inventors: **Sucheta Telang** and Jason Chesney

United States Patent # **8,557,823 B2**, **October, 2013**

Family of PFKFB3 inhibitors with anti-neoplastic activities

Inventors: Gilles H. Tapolsky, Pooran Chand, John O. Trent, **Sucheta Telang**, Brian F. Clem and Jason Chesney

**Pending United States Patents (currently under review):**

Small Molecule Inhibitors of PFKFB3 and Glycolytic Flux and Their Methods of Use as Anti-Cancer Therapeutics

Inventors: Pooran Chand, Jason Chesney, Brian F. Clem, Gilles H. Tapolsky, **Sucheta Telang** and John O. Trent

Application Number: US2011/025691

Compounds and Methods For Using Compounds That Inhibit Choline Kinase

Inventors: Jason Chesney, John O. Trent, **Sucheta Telang** and Brian Clem

Application Number: 61/220,620

**EDITORIAL WORK**

2006-present **Ad hoc Reviewer**, Cellular and Molecular Biology Letters

2006-present **Ad hoc Reviewer**, Biomaterials

2009-present **Ad hoc Reviewer**, Molecular Cancer

2013-present **Ad hoc Reviewer**, Cancer Research

2013-present **Ad hoc Reviewer**, Carcinogenesis

2012-present **Member, Review Board**, Journal of Pediatric Biochemistry

**ABSTRACTS AND PRESENTATIONS**

**Oral Presentations, International/National Meetings:**

05/02/04 “**Bacterial Growth Rates in Preterm Human Milk Fortified with Powdered Fortifiers**” Oral Presentation. Society for Pediatric Research Meeting, San Francisco, CA.

02/25/05 “**Inducible 6-Phosphofructo-2-kinase is an essential downstream effector of the oncogene ras**” American Federation for Clinical Research, Southern Society for Clinical Investigation Annual Meeting, New Orleans, LA.

08/14/06 “**Ascorbic Acid: An Essential Vitamin for Tumor Growth?**” International Society for Oxygen Transport to Tissues, Louisville, KY.

- 07/16/10 **“Targeting 6-phosphofructo-2-kinase 4 (PFKFB4) in Lung Cancer”**, American Cancer Society Research Day, Louisville, KY.
- 03/18/11 **“Targeting Glucose Metabolism in Cancer”**, American Cancer Society Research Day, Louisville, KY.
- 04/13/11 **“PFKFB2-PFKFB4 and Tumor cell Metabolism”**, Oral Presentation, Metabolism and Cancer Therapeutics Workshop, Louisville, KY.
- 04/30/12 **“Requirement of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase Isoform 4 (PFKFB4) for Anchorage Independent Growth and Tumorigenesis”**, Pediatric Academic Societies Meeting, Boston, MA.
- 05/15/12 **“The PFKFB Family of Enzymes and Tumor Metabolism”**, Banbury Meeting on Regulation of Metabolism in Cancer, Cold Spring Harbor Laboratory, Long Island, NY.
- 05/06/13 **“Targeting 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 (PFKFB4) in Cancer”**, Pediatric Academic Societies Meeting, Washington, DC.

#### Oral Presentations, University of Louisville:

- 04/07/03 **“Scurvy: A Possible Cure for Cancer?”**, Pediatric Research Seminar Series, Kosair Childrens Hospital, U of L.
- 05/22/03 **“An Orange a Day May Not Keep the Doctor Away”**, Molecular Targets Seminar Series, U of L.
- 09/10/03 **“Do Oranges Cure Cancer?”**, Molecular Targets Program Retreat.
- 03/02/06 **“A New View at C: Giving Cancer Patients Scurvy”**, Molecular Targets Seminar Series, U of L.
- 06/25/09 **“Targeting Glucose Metabolism in Cancer”**, Molecular Targets Seminar Series, U of L.
- 05/03/10 **“Inborn Errors of Metabolism- Case studies”**, Medical Biochemistry, U of L
- 08/09/10 **“Targeting Glucose Metabolism in Cancer”**, Department of Biochemistry Seminar Series, U of L.
- 10/11/10 **“A Trial of Recombinant Human Lactoferrin (Talactoferrin) in Preterm Newborns”**, Department of Pediatrics Research Grand Rounds, U of L.
- 05/16/11 **“Targeting Metabolism in Cancer Cells”**, Regional Cancer Center Board Meeting, U of L.
- 08/24/11 **“Panel Discussion: Grants and Funding”**, MD/PhD Program, U of L.
- 10/26/12 **“The Mighty Mouse - Ideas for a Murine Models Core”**, Brown Cancer Center Retreat.

#### Poster Presentations, International/National Meetings:

- 05/02/04 **“Bacterial Growth Rates in Preterm Human Milk Fortified with Powdered Fortifiers.”** Society for Pediatric Research Meeting, San Francisco, CA.
- 05/15/05 **“Inducible 6-Phosphofructo-2-kinase (iPFK2; PFKFB3) is an essential downstream effector of ras.”** Society for Pediatric Research Annual Meeting, Washington D.C.
- 11/14/05 **“Immortalization is Sufficient to Cause the Major Metabolic Alterations of Cancer”**, American Association for Cancer Research, NCI-EORTC International Conference, Philadelphia, PA (Clinical Cancer Research 2005; 11(24), 9142s).
- 11/14/05 **“The Inducible Isozyme of 6-Phosphofructo-2-Kinase is An Essential Downstream Effector of the Oncogene Ras”**. American Association for Cancer Research NCI-EORTC International Conference, Philadelphia, PA (Clinical Cancer Research 2005; 11(24), 9142s).
- 02/07/06 **“Ascorbate (Vitamin C): Friend or Foe in the Fight Against Cancer”**. Gordon Conference on Oxygen Radicals, Ventura, CA.
- 05/01/06 **“Inducible 6-Phosphofructo-2-Kinase (iPFK-2;PFKFB3) is an Essential Downstream Effector of the Oncogene Ras”**. Society for Pediatric Research Annual Meeting, San Francisco, CA.
- 10/23/07 **“Requirement of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 (PFKFB4) for Anchorage Independent Growth and Tumorigenesis”**. American Association for Cancer Research, NCI-EORTC International Conference, San Francisco, CA (Molecular Cancer Therapeutics 2007; 6(12): 3363s).
- 10/23/07 **“Small molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth”**. American Association for Cancer Research, NCI-EORTC International Conference, San Francisco, CA (Molecular Cancer Therapeutics 2007; 6(12): 3363s).
- 05/02/09 **“Requirement of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 (PFKFB4) for Anchorage Independent Growth and Tumorigenesis”**. Society for Pediatric Research Meeting, Baltimore, MD.
- 02/26/10 **“Requirement of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 (PFKFB4) for Anchorage Independent Growth and Tumorigenesis”**. Southern Society for Clinical Investigation Meeting, 2010, New Orleans, LA.
- 06/06/11 **“Denileukin diftitox increases serum GM-CSF and causes durable clinical responses that are associated with prolonged survival in stage IV melanoma”**. American Society for Clinical Oncology, 2011, Chicago, IL.
- 02/27/13 **“Targeting 6-Phosphofructo-2-kinase/Fructose-2,6-Bisphosphatase-4 (PFKFB4) in Lung Cancer”**. Keystone Meeting on Tumor Metabolism, Keystone, CO.

**Poster Presentations, University of Louisville:**

- 09/22/03 **JGBCC, University of Louisville Second Annual Retreat**  
 1. "Silencing of iPFK-2 Causes a Global Decrease in Nucleic Acid and Protein Synthesis in Cancer Cells."  
 2. "Universal Virus Detection."
- 09/23/04 **JGBCC, University of Louisville Third Annual Retreat**  
 1. "Nuclear Localization of Inducible 6-Phosphofructo-2-Kinase (iPFK-2; PFKFB3)."  
 2. "Inducible 6-Phosphofructo-2-Kinase (iPFK-2;PFKFB3) is an Essential Downstream Effector of the Oncogene Ras."  
 3. "Ascorbate (Vitamin C): Friend or Foe in the Fight Against Cancer?."  
 4. "Genomic Deletion of Inducible 6-Phosphofructo-2-Kinase (PFKFB3) is Lethal."  
 5. "Upregulation of Inducible 6-Phosphofructo-2-Kinase (iPFK-2) During T Cell Activation."  
 6. "Pharmacophore Targeting of the Fructose-6-Phosphate Binding Site of iPFK-2 Suppresses Tumor Growth. "
- 11/09/04 **Research! Louisville, University of Louisville**  
 1. "Pharmacophore Targeting of the Fructose-6-Phosphate Binding Site of iPFK-2 Suppresses Tumor Growth."  
 2. "Inducible 6-Phosphofructo-2-Kinase (iPFK-2;PFKFB3) is an Essential Downstream Effector of the Oncogene Ras."  
 3. "Nuclear Localization of Inducible 6-Phosphofructo-2-Kinase (iPFK-2; PFKFB3)."
- 09/14/05 **JGBCC, University of Louisville Fourth Annual Retreat (The Olmsted)**  
 1. "Pharmacologic Inhibition of 6-Phosphofructo-2-Kinase (PFKFB3) Suppresses Cancer Cell Proliferation."  
 2. "Radiation Protection with Iron Chelation."  
 3. "High Choline Kinase Activity is Essential for Neoplastic Proliferation."  
 4. "The Regulatory Subunit Vb of Cytochrome c Oxidase is Required for Malignant Transformation."  
 5. "The Inducible Isozyme of 6-Phosphofructo-2-Kinase (PFKFB3) is an Essential Downstream Effector of the Oncogene Ras."  
 6. "Immortalization is Sufficient to Cause the Major Metabolic Alterations of Cancer."  
 7. "Role of Lactate Dehydrogenase A (LDH-A) in c-Myc Mediated Oncogenic Transformation."  
 8. "Nuclear Compartmentalization of a Key Regulator of Glycolysis, 6-Phosphofructo-2-Kinase (PFKFB3)."
- 05/15/06 **JGBCC Molecular Targets Program Annual Retreat (The Brown Hotel)**  
 1. "Pharmacologic Targeting of 6-Phosphofructo-2-Kinase."  
 2. "Ascorbate: Friend or Foe in the Fight Against Cancer."

3. "The Inducible Isozyme of 6-Phosphofructo-2-Kinase Is an Essential Downstream Effector of the Oncogene Ras."

11/29/06 **JGBCC, University of Louisville Fifth Annual Retreat (The Olmsted)**

1. "Requirement of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase- 4 (PFKFB4) for Anchorage Independent Growth and Tumorigenesis."
2. "Pharmacological Inhibition of 6-phosphofructo-2-kinase (PFKFB3) Suppresses Tumor Growth."
3. "PFKFB3 Interacts with C-RAF."

11/28/07 **JGBCC, University of Louisville Sixth Annual Retreat (The Olmsted)**

1. "Small Molecule Inhibition of 6-Phospho-2-Kinase Activity Suppresses Glycolytic Flux and Tumor Growth."
2. "Transient T Cell Depletion Causes Regression of Melanoma Metastases."
3. "Requirement of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase- 4 (PFKFB4) for Tumorigenesis."
4. "6-Phosphofructo-2-Kinase Trafficks to the Nucleus and Stimulates Cell Proliferation. "

11/29/08 **JGBCC, University of Louisville Seventh Annual Retreat (The Olmsted)**

1. "Requirement of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase- 4 (PFKFB4) for Anchorage Independent Growth and Tumorigenesis."
2. "Inhibition of 6-Phosphofructo-2-kinase Suppresses Breast Tumor growth *in vivo*."
3. "Small Molecule Targeting of Choline Kinase Decreases Tumor Growth *in vitro* and *in vivo*."
4. "The Regulatory Subunit Vb of Cytochrome C Oxidase is Required for Malignant Transformation. "
5. "Transient T Cell Depletion with DAB/IL2 Causes Regression of Melanoma Metastases: Results of the First 37 Patients."
6. "6-Phosphofructo-2-kinase/ Fructose2,6 Bisphosphatase-3 (PFKFB3) Localizes to the Nucleus and Enhances Cyclin-Dependent Kinase Activity and the Phosphorylation of the Cell Cycle Inhibitor p27<sup>Kip1</sup>."
7. "Selective Inhibition of Choline Kinase Interrupts Ras Signaling and Tumor Growth."

11/6/09 **JGBCC, University of Louisville Eighth Annual Retreat (The Olmsted)**

1. "P27 Is Required for Growth Defects and Apoptosis Caused by

PFKFB3 Inhibition.”

2. “Selective Inhibition of Choline Kinase Simultaneously Attenuates MAPK and PI3K/AKT Signaling.”
3. “Identification of Bacterial Species in the Ohio River Using Random Multiplex (RT)-PCR With 3'-Locked Random Primers.”
4. “Small Molecule Targeting of Choline Kinase Decreases Tumor Growth In Vitro and In Vivo.”
5. “Regulatory Subunit Vb of Cytochrome c Oxidase is Required for Malignant Transformation.”
6. “Association of Clinical Response to Recombinant IL-2/Diphtheria Toxin with Increased Survival In Stage IV Melanoma Patients.”
7. “Requirement of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase Isoform 4 (PFKFB4) for Anchorage Independent Growth and Tumorigenesis.”

03/27/10

**Joint UK/UofL Lung Cancer Conference, Lexington, KY**

1. “Requirement of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase Isoform 4 (PFKFB4) for Anchorage Independent Growth and Tumorigenesis. “
2. “Small Molecule Inhibition of 6-Phosphofructo-2-Kinase Activity Suppresses Glycolytic Flux and Tumor Growth.”

10/12-15/11

**Research!Louisville (Louisville, KY)**

1. “PFKFB3 is required for Resistance to Apoptosis under Hypoxia.”

11/5/10

**JGBCC, University of Louisville Ninth Annual Retreat (The Olmsted)**

1. “ Clinical Responses to the Regulatory T –Cell Depleting Agent , Denileukin Diftitox, are Associated with Prolonged Survival In Stage IV Melanoma Patients.”
2. “Micelle Encapsulation of the Glycolytic Inhibitor 3PO as a Therapeutic Delivery Formulation.”
3. “Small Molecule Targeting of Choline Kinase Decreases Tumor Growth In Vitro and In Vivo.”
4. “PFKFB3 is required for Resistance to Apoptosis under Hypoxia.”

10/17-21/11

**Research!Louisville (Louisville, KY)**

1. “Starvation induced by glycolytic inhibition promotes autophagy in neoplastic cells.”
2. “Glutathione Synthetase Is Required for the Anchorage Independent Growth of A549 Lung Adenocarcinoma Cells.”
3. “ Characterization of a novel small molecule antagonist (PFK-015) of 6-Phosphofructo-2-kinase/ fructose-2,6-bisphosphatase-3 (PFKFB3) that suppresses glucose metabolism and tumor growth.”

10/28/11

**JGBCC, University of Louisville Tenth Annual Retreat (The Olmsted)**

1. "Requirement of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase Isoform 4 (PFKFB4) for Anchorage Independent Growth and Survival in Breast Adenocarcinoma Cells."
2. "Characterization of a novel small molecule antagonist (PFK-015) of 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) that suppresses glucose metabolism and tumor growth."
3. "Loss of Retinoblastoma Protein alters Glucose and Glutamine Metabolism."
4. "Glutathione Synthetase is Required for the Anchorage independent Growth of A549 cells."
5. "Starvation induced by glycolytic inhibition promotes autophagy in neoplastic cells."

10/26/12 **JGBCC, University of Louisville Eleventh Annual Retreat (The Olmsted)**

"Targeting 6-Phosphofructo-2-Kinase (PFKFB3) as a Therapeutic Strategy Against Cancer"

10/25/13 **JGBCC, University of Louisville Twelfth Annual Retreat (The Olmsted)**

1. "6-Phosphofructo-2-Kinase Induces Autophagy as a Survival Mechanism"

2. "Targeting Human 6-Phosphofructo-2-Kinase/Fructose 2,6 bisphosphatase-4."

10/17/14 **JGBCC, University of Louisville Twelfth Annual Retreat (The Olmsted)**

1. "Targeting 6-Phosphofructo-2-Kinase/Fructose 2,6 bisphosphatase-4 for the Treatment of Lung Cancer."

## PUBLICATIONS

### Peer-Reviewed Research Publications

Communicating author (§)

1. **Telang S**, Vimr E, Mahoney J, Law I, Lundqvist – Gustafsson H, Qian M and Eaton J. Strain -specific iron- dependent virulence in *Escherichia coli*. **Journal of Infectious Diseases**, 2001,(184):159-65. PMID: 11424012
2. Sehgal A, **Telang S**, Passah SM, Jyothi MC. Maternal and neonatal profile and outcomes in very low birth weight infants. **Indian Pediatrics**, 2003, 40:991-995. PMID:14581739

3. Sehgal A, **Telang S**, Passah SM, Jyothi MC. Maternal and neonatal profile and immediate outcome in extremely low birth weight babies in Delhi. *Trop Doct*; 2004, 34(3):165-8. PMID:15267050
4. Chesney, J, **Telang S**, Yalcin, T, Clem, A, Wallis, N and Bucala R. Targeted Disruption of Inducible 6-Phosphofructo-2-Kinase Results in Embryonic Lethality. *Biochemical and Biophysical Research Communications*, 2005, 331(1):139-46. PMID: 15845370
5. **Telang S**, Berseth CL, Ferguson P, Kinder J, DeRoin M, Petschow B. Fortifying Fresh Human Milk with Commercial Powdered Human Milk Fortifiers Does Not Affect Bacterial Growth During 6 Hours at Room Temperature. *Journal of the American Dietetic Association*, 2005,105(10):1567-72. PMID: 16183356
6. **Telang S**, Yalcin A, Clem AL, Bucala R, Lane AN, Eaton JW, Chesney J. Ras Transformation Requires Metabolic Control by 6-Phosphofructo-2-Kinase. *Oncogene*, 2006, 25(55):7225-34. PMID: 16715124
7. **Telang S**, Clem, AL, Eaton, JW, and Chesney J. Depletion of Ascorbic Acid Restricts Angiogenesis and Retards Tumor Growth in a Mouse Model. *Neoplasia*, 2007, 9(1): 47-56. PMID: 17325743
8. Clem, A, Sims, J, Eaton, JW, **Telang S**, and Chesney, J. Virus detection and identification using random multiplex (RT)-PCR with 3'-locked random primers. *Virology Journal*, 2007, 4(1):65. PMID: 17598900
9. **Telang S**, Nelson, K, Lane, A, and Chesney, J. The Oncoprotein H-RasV12 Increases Mitochondrial Metabolism. *Molecular Cancer*, 2007, 6:77-83. PMID: 18053146
10. Clem, B, **Telang S**, Clem, A, Yalcin, A, Meier, J, Simmons, A, Rasku, M, Dean, W, Trent, JO, and Chesney, J. Small Molecule Inhibition of 6-Phosphofructo-2-Kinase Activity Suppresses Established Tumor Growth. *Molecular Cancer Therapeutics*, 2008, 7(1):110-20. PMID: 18202014
11. Rasku, M, Clem, AL, **Telang S**, Taft, B, Gettings, K, Gragg, H, Cramer, D, Lear, SC, McMasters, KM, Miller, DM, and Chesney J. Transient T Cell Depletion Causes Regression of Melanoma Metastases. *Journal of Translational Medicine*, 2008, 6(1):12. PMID: 18334033
12. Thornburg, JM, Nelson, KK, Lane, AN, Arumugam, S, Simmons, A, Eaton, JW, **Telang S**, Chesney, J. Targeting Aspartate Aminotransferase in Breast Cancer *Breast Cancer Research*, 2008, 10(5):R84. PMID: 18922152



13. Liu Y, Clem B, Zuba-Surma EK, El-Naggar S, **Telang S**, Jenson AB, Wang Y, Shao H, Ratajczak MZ, Chesney J and Dean DC. Mouse fibroblasts lacking RB1 function form spheres and undergo reprogramming to a cancer stem cell phenotype. **Cell Stem Cell**, 2009; 4 (4): 336-347. PMID: 19341623
14. Yalcin A, Clem BF, Simmons A, Lane A, Nelson K, Clem AL, Brock E, Siow D, Wattenberg B, **Telang S** and Chesney J. Nuclear targeting of 6-phosphofructo-2-kinase (PFKFB3) increases proliferation via cyclin-dependent kinases. **Journal of Biological Chemistry**, 2009, 284(36):24223-32. PMID: 19473963
15. Yalcin A, **Telang S**, Clem B, Chesney J. Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6 bisphosphatases in cancer. **Experimental and Molecular Pathology**. 2009, 86(3): 174-179. PMID: 19454274
16. Yalcin A, Clem BF, Makoni S, Clem A, Nelson K, Thornburg J, Siow D, Lane AN, Brock SE, Goswami U, Eaton JW, **Telang S** and Chesney J. Selective Inhibition of Choline Kinase Simultaneously Attenuates MAPK and PI3K/AKT Signaling. **Oncogene**, 2010, 7;29 (1):139-49. PMID: 19855431
17. Huo Y, Guo X, Li H, Wang H, Zhang W, Wang Y, Zhou H, Gao Z, **Telang S**, Chesney J, Chen YE, Ye J, Chapkin RS, Wu C. Disruption of inducible 6-phosphofructo-2-kinase ameliorates diet-induced adiposity but exacerbates systemic insulin resistance and adipose tissue inflammatory response. **Journal of Biological Chemistry**, 2010, 285(6):3713-21. PMID: 19948719
18. Clem BF, Clem AL, Yalcin A, Goswami U, Arumugam S, **Telang S**, Trent JO, Chesney J. A novel small molecule antagonist of choline kinase- $\alpha$  that simultaneously suppresses MAPK and PI3K/AKT signaling. **Oncogene**, 2011, 28;30(30):3370-80. PMID 21423211
19. Natarajan N, **Telang S**, Miller D, Chesney J. Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma. **Drugs**. 2011, 9;71 (10):1233-50. PMID 21770473
20. **Telang S**, Rasku MA, Clem AL, Carter K, Klarer AC, Badger WR, Milam RA, Rai SN, Pan J, Gragg H, Clem BF, McMasters KM, Miller DM, and Chesney J. Phase II Trial of the Regulatory T Cell-Depleting Agent, Denileukin Diftitox, in Patients with Unresectable Stage IV Melanoma. **BMC Cancer**, 2011 13;11(1):515. PMID: 22165955
21. Chesney J§ and **Telang S**§. Regulation of glycolytic and mitochondrial metabolism by Ras. **Current Pharmaceutical Biotechnology**, 2012, 14(3):251-60. PMID: 22201601 (§dual communicating).
22. **Telang, S**§, Clem, BF, Klarer, AC, Clem, AL, Trent, JO, Bucala, R and Chesney,

- J§. Small Molecule Inhibition of 6-Phosphofructo-2-Kinase Suppresses T Cell Activation. *Journal of Translational Medicine*, 2012,16;10(1):95. PMID: 22591674 (§dual communicating).
23. **Telang, S**, Nelson, KK, Siow, DL, Yalcin, A, Thornburg, JM, Eaton, JW, Clem, AL, Imbert-Fernandez, Y, Klarer, AC, Farghaly, H, Clem, BF, and Chesney J. Cytochrome c oxidase is activated by the oncoprotein Ras and is required for A549 lung adenocarcinoma growth. *Molecular Cancer*, 2012, 11(1):60. PMID: 22917272
24. Liu Y., Sanchez-Tillo E., Lu X., Huang L., Clem B., **Telang S.**, Jenson A., Cuatrecasas M., Chesney J., Postigo A., and Dean, D. Sequential Inductions of the ZEB1 Transcription Factor Caused by Mutation of Rb and then Ras are required for Tumor Initiation and Progression. *Journal of Biological Chemistry*, 2013, 288(16):11572-80. PMID: 23443660
25. Clem BF, O'Neal J, Tapolsky G, Clem AL, Imbert-Fernandez Y, Kerr DA 2nd, Klarer A, Redman R, Miller DM, Trent JO, **Telang S.**, Chesney J. Targeting 6-Phosphofructo-2-Kinase (PFKFB3) as a Therapeutic Strategy against Cancer. *Molecular Cancer Therapeutics*, 2013, 12(8) 1-10. PMID: 23674815
26. De Bock K, .... Rider M, Van Veldhoven PP, Schuit F, Bartrons R, Hofkens J , Fraisl P, **Telang S**, DeBerardinis RJ, Schoonjans L, Vinckier S, Chesney J, Gerhardt H, Dewerchin M and Peter Carmeliet. Role of PFKFB3-driven Glycolysis in Vessel Sprouting. *Cell*, 2013, 154(3):651-63. PMID: 23911327
27. Liu Y, Sánchez-Tilló E, Lu X, Clem B, **Telang S**, Jenson AB, Cuatrecasas M, Chesney J, Postigo A and Dean DC. Rb1 family mutation is sufficient for sarcoma initiation. *Nature Communications*. 2013, 4:2650. PMID: 24150016
28. Schoors S, ... **Telang S**, Cascante M, Chesney J, Dewerchin M and Carmeliet P. Partial and Transient Reduction of Glycolysis by PFKFB3-blockade Reduces Pathological Angiogenesis. *Cell Metabolism*, 2014,19(1):37-48. PMID: 24332967
29. Liu Y, Sanchez-Tillo E, Lu X, Huang L, Clem B, **Telang S**, Jenson AB, Cuatrecasas M, Chesney J, Postigo A, Dean DC. The ZEB1 Transcription Factor Acts in a Negative Feedback Loop with miR200 Downstream of Ras and Rb1 to Regulate Bmi1 Expression. *Journal of Biological Chemistry*. 2013, 289(7):4116-25. PMID: 24371144
30. Klarer, A.C., O'Neal, J., Imbert-Fernandez, Y., Clem, A.L., Ellis, S.R., Clark, J., Clem, B.F., Chesney, J. and **Telang, S§**. Inhibition of 6-Phosphofructo-2-Kinase (PFKFB3) Induces Autophagy as a Survival Mechanism. *Cancer and*

**Metabolism**, 2014, 2(1):2. PMID: 24451478

31. Imbert-Fernandez Y., Spaulding R., Lanceta L., Clem B.F., O'Neal J., Clem A., **Telang S.** and Chesney J. Estradiol Stimulates Glucose Metabolism via 6-Phosphofructo-2-Kinase (PFKFB3). *In press, Journal of Biological Chemistry*, 2014, 289(13):9440-8. PMID: 24515104 (§dual communicating).
32. Yalcin A, Clem BF, Imbert-Fernandez Y, Ozcan SC, Peker S, O'Neal J, Klarer AC, Clem AL, **Telang S**, Chesney J 6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27. **Cell Death and Disease**, July, 2014;5:e1337. PMID 25032860
33. Chesney J., Clark J., Klarer A., Imbert-Fernandez Y., Lane A. and **Telang S.** Fructose-2,6-Bisphosphate synthesis by 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth. **Oncotarget**, 5(16):6670-862014. PMID 25115398